CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...